Literature DB >> 17333500

Tuberous sclerosis successfully treated with levetiracetam monotherapy: 18 months of follow-up.

Savvas S Papacostas1, Eleftherios S Papathanasiou, Panayiota Myrianthopoulou, Goula Stylianidou.   

Abstract

CASE: We present the case of a boy with tuberous sclerosis who was referred for evaluation and treatment of his intractable epileptic seizures, having failed multiple anti-epileptic drug trials. He was subsequently treated with Levetiracetam that was gradually titrated to an effective dose, achieving full suppression of his seizures. Thereafter, his concomitant anti-epileptic drugs were gradually reduced and eventually discontinued. He remained on monotherapy with Levetiracetam, which continued to fully control his seizures. His EEG tracings before and after treatment are presented and compared, showing normalization of the latter.
CONCLUSION: Levetiracetam appears to be effective in treatment-resistant seizures which are symptomatic to tuberous sclerosis when used adjunctively as well as in monotherapy. This is the first report in the English literature regarding its use and efficacy in this condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17333500     DOI: 10.1007/s11096-007-9085-3

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  10 in total

Review 1.  Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy.

Authors:  J C Cloyd; R P Remmel
Journal:  Pharmacotherapy       Date:  2000-08       Impact factor: 4.705

Review 2.  The tuberous sclerosis complex.

Authors:  Peter B Crino; Katherine L Nathanson; Elizabeth Petri Henske
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

3.  Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial.

Authors:  Giangennaro Coppola; Emilio Franzoni; Alberto Verrotti; Caterina Garone; Jasenka Sarajlija; Francesca Felicia Operto; Antonio Pascotto
Journal:  Brain Dev       Date:  2006-10-20       Impact factor: 1.961

4.  Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices.

Authors:  I Niespodziany; H Klitgaard; D G Margineanu
Journal:  Neurosci Lett       Date:  2001-06-22       Impact factor: 3.046

Review 5.  Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects.

Authors:  Mary B Connolly; Glenda Hendson; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2006-06-13       Impact factor: 1.475

6.  Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.

Authors:  Cai Ji-qun; Kumatoshi Ishihara; Takashi Nagayama; Tadao Serikawa; Masashi Sasa
Journal:  Epilepsia       Date:  2005-09       Impact factor: 5.864

7.  Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study.

Authors:  Angelo Labate; Eleonora Colosimo; Antonio Gambardella; Ugo Leggio; Roberta Ambrosio; Aldo Quattrone
Journal:  Seizure       Date:  2006-01-18       Impact factor: 3.184

8.  The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents.

Authors:  J-M Rigo; G Hans; L Nguyen; V Rocher; S Belachew; B Malgrange; P Leprince; G Moonen; I Selak; A Matagne; H Klitgaard
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

9.  Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial.

Authors:  James J Collins; Cynthia Tudor; Jennifer M Leonard; Gail Chuck; David Neal Franz
Journal:  J Child Neurol       Date:  2006-01       Impact factor: 1.987

10.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

Authors:  Berkley A Lynch; Nathalie Lambeng; Karl Nocka; Patricia Kensel-Hammes; Sandra M Bajjalieh; Alain Matagne; Bruno Fuks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

  10 in total
  1 in total

Review 1.  Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review.

Authors:  Amerins Weijenberg; Oebele F Brouwer; Petra M C Callenbach
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.